里昂升药明康德(2359.HK)目标价至98.84港元经调整纯利略胜预期
里昂发表研究报告,指药明康德(02359.HK)上半年收入录58.94亿元人民币(下同),按年增长33.7%。经调整盈利10.79亿元,按年增加22.3%,略高于该行全年预测(对应半年计)。期内,公司新增客户近600家,并正进行800多个小分子药项目。

该行维持其“买入”投资评级,目标价由原来的88.83港元上调至98.84港元,相当于2021年预测市盈率41倍。基於其好过预期的上半年业绩,产能持续扩张及综合服务平台,有助吸引更多新客户及维系现有客户,相信长远而言,公司将会继续维持强劲的增长,将其2019至2021年各年的收入增长预测分别提升至34.9%、27.5%及24.6%,并预期2019至2021年各年的经调整纯利分别按年增长33.1%、24.8%及23.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.